Helicobacter pylori infection: Treatment

Current Opinion in Gastroenterology

Volumn 18, Issue 1, 2002, Pages 26-33

  Belhoussine Idrissi, Lila ^a   Boedeker, Edgar C ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR;

ANTIBIOTIC RESISTANCE; DRUG SENSITIVITY; ERADICATION THERAPY; FOLLOW UP; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RATE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PEPTIC ULCER; POLYP; REVIEW; STOMACH CARCINOMA; STOMACH DISEASE; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0036137891     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200201000-00005     Document Type: Review

References (70)

1. Strategy for treatment of Helicobacter pylod infection in adults II. Practical policy in 2000
2. Pooled analysis of Helicobacter pylori eradication regimes in Asia
3. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole
4. The AMOR study: A randomized, double-blinded trial of omeprazole versus ranitidine together with amoxicillin and metronidazole for eradication of Helicobacter pylori
5. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen
6. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children
7. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States
8. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada
9. Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group
10. Helicobacter pylori antibiotic resistance: Trends over time
11. Antibiotic-resistant H. pylori infection and its treatment
12. A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection
13. The HOMER study: The effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection
14. Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: Advantages and outcome
15. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication
16. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: A prospective study
17. Effects of in vitro antibiotic resistance on treatment: Bismuth- containing regimens
18. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo
19. Retreatment of Helicobacter pylori infection after initial treatment failure
20. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: Effect of metronidazole resistance
21. Randomized study of 2 "rescue" therapies for Helicobacter pylori- infected patients after failure of standard triple therapies
22. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience
23. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of H. pylori
24. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: A pilot study
25. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
26. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man
27. Diagnosis of Helicobacter pylori infection: Noninvasive methods compared to invasive methods and evaluation of 2 new tests
28. Concordance between noninvasive tests in detecting Helicobacter pylori and potential use of serology for monitoring eradication in gastric ulcer
29. Usefulness of Helicobacter pylori stool antigen test to monitor response to eradication treatment in children
30. Posttreatment follow-up of Helicobacter pylori infection using a stool antigen immunoassay
31. The accuracy of the Helicobacter pylori stool antigen test in diagnosing H. pylori in treated and untreated patients
32. Posttreatment diagnostic accuracy of a new enzyme immunoassay to detect Helicobacter pylori in stools
33. Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy
34. Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000
35. Treatment of Helicobacter pylori: An overview
36. Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease: A randomized trial with 2-year follow-up
37. Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage
38. Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage: A long-term randomized, controlled study
39. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage
40. Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma: A long-term follow-up study
41. Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment
42. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori
43. Histological and immunological parameters to predict treatment outcome of Helicobacter pylori eradication in low-grade gastric MALT lymphoma
44. Microsatellite instability at D18S61 is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication
45. Resistance of t(11, 18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
46. When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after Helicobacter pylori eradication?
47. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial
48. Is there any relationship between functional dyspepsia and chronic gastritis associated with Helicobacter pylori infection?
49. The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan
50. Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: The search for an improbable consensus
51. Interaction of Helicobacter pylori eradication and non-steroidal anti- inflammatory drugs on gastric epithelial apoptosis and proliferation: Implications on ulcerogenesis
52. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects
53. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression
54. Helicobacter pylori eradication dramatically improves inflammation in the gastric cardia
55. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan
56. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation
57. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors
58. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy
59. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated
60. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients
61. Long-term effects of Helicobacter pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers
62. Is Helicobacter pylori infection in childhood a risk factor for gastric cancer?
63. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?
64. Curing Heticebacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease
65. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial
66. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis
67. Management of Helicobacter pylori in duodenal ulcer: A cost- effectiveness analysis
68. Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy
69. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia
70. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia